MCID: BCL006
MIFTS: 70

B-Cell Lymphomas

Categories: Rare diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for B-Cell Lymphomas

MalaCards integrated aliases for B-Cell Lymphomas:

Name: B-Cell Lymphomas 37 72 69
B-Cell Lymphoma 12 49 28 14
Lymphoma, B-Cell 49 41
B-Cell Lymphocytic Neoplasm 12
Lymphoma B-Cell 51

Classifications:



External Ids:

Disease Ontology 12 DOID:707
MeSH 41 D016393
NCIt 46 C27907 C3457
UMLS 69 C0079731

Summaries for B-Cell Lymphomas

NIH Rare Diseases : 49 B-cell lymphoma refers to types of non-Hodgkin lymphoma that are characterized by abnormalities of the "B-cells" (a type of white blood cell that makes antibodies to help fight infection). The condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms. When present, signs and symptoms may include swollen lymph nodes in the neck, armpit, or groin; abdominal pain; fatigue; fever; night sweats; and/or weight loss. The underlying cause of B-cell lymphoma is poorly understood. However, the condition can be associated with genetic abnormalities, environmental factors, viruses, immunodeficiency states, and connective-tissue disorders. Treatment is based on many factors, including the severity of the condition and the associated signs and symptoms. Last updated: 1/10/2016

MalaCards based summary : B-Cell Lymphomas, also known as b-cell lymphoma, is related to t-cell/histiocyte rich large b cell lymphoma and nodal marginal zone b-cell lymphoma. An important gene associated with B-Cell Lymphomas is BCL6 (B Cell CLL/Lymphoma 6), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Adcetris and Bexxar have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A non-Hodgkin lymphoma that has material basis in B cells.

Wikipedia : 72 Lymphoma is a group of blood cancers that develop from lymphocytes (a type of white blood cell). The... more...

Related Diseases for B-Cell Lymphomas

Diseases in the B-Cell Lymphomas family:

T-Cell Lymphoma 1a

Diseases related to B-Cell Lymphomas via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 561)
# Related Disease Score Top Affiliating Genes
1 t-cell/histiocyte rich large b cell lymphoma 34.7 BCL6 MME TNFRSF8
2 nodal marginal zone b-cell lymphoma 34.6 BCL2 BCL6 MALT1
3 diffuse large b-cell lymphoma of the central nervous system 34.6 BCL2 MYC
4 primary cutaneous marginal zone b-cell lymphoma 34.5 BCL10 IRF4 MALT1
5 primary mediastinal large b-cell lymphoma 34.5 BCL6 FOXP1 IRF4
6 splenic diffuse red pulp small b-cell lymphoma 34.5 CCND3 TP53
7 intravascular large b-cell lymphoma 34.3 BCL2 BCL6 CD5 MME
8 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 34.2 BCL2 BCL6 MYC
9 marginal zone b-cell lymphoma 33.9 BCL10 BCL2 BCL6 CCND1 CD5 IRF4
10 lymphoma, mucosa-associated lymphoid type 33.1 BCL10 BCL2 BCL6 CCND1 CD5 FOXP1
11 splenic marginal zone lymphoma 33.0 BCL6 CD5 MALT1 PAX5
12 primary effusion lymphoma 32.9 BCL6 CDKN1B IRF4 MYC
13 mediastinal gray zone lymphoma 32.9 BCL6 PAX5 REL TNFRSF8
14 diffuse large b-cell lymphoma 32.8 BCL10 BCL6 CCND1 CD5 FOXP1 IRF4
15 richter's syndrome 32.7 CD5 IRF4 MYC TP53
16 reticulosarcoma 32.1 BCL6 CCND3 PAX5 TNFRSF8
17 primary central nervous system lymphoma 31.8 BCL2 BCL6 PAX5
18 mature b-cell neoplasm 31.7 AICDA BCL6 MME MYC TP53
19 lymphoma 31.5 BAX BCL10 BCL2 BCL6 CCND1 MALT1
20 burkitt lymphoma 31.4 AICDA BAX BCL6 CCND3 MS4A1 MYC
21 nodular lymphocyte predominant hodgkin lymphoma 31.1 BCL6 CCND1 PAX5
22 follicular lymphoma 31.1 AICDA BCL10 BCL2 BCL6 CCND1 CCND3
23 lymphoma, hodgkin, classic 30.9 BCL6 IRF4 MS4A1 PAX5 REL TNFRSF8
24 composite lymphoma 30.9 BCL6 CD5 PAX5
25 follicular lymphoma 1 30.7 BCL10 BCL2 BCL6
26 central nervous system lymphoma 30.7 BCL6 FOXP1 MALT1 TP53
27 prolymphocytic leukemia 30.6 CCND1 CD5 MYC
28 myeloma, multiple 30.5 CCND1 CCND3 IRF4 MYC TP53
29 t-cell prolymphocytic leukemia 30.5 CDKN1B MS4A1 MYC
30 acquired immunodeficiency syndrome 30.5 BCL6 MYC TP53
31 lymphoblastic lymphoma 30.4 BCL6 CD5 MME
32 breast lymphoma 30.4 BCL6 CD5
33 adult lymphoma 30.4 CD5 MYC TNFRSF8
34 retinoblastoma 30.4 CCND1 CCND3 CDKN1B TP53
35 mantle cell lymphoma 30.4 BCL2 BCL6 CCND1 CCND3 CD5 CDKN1B
36 gastric lymphoma 30.2 BAX BCL10 BCL2 BCL6 TP53
37 breast adenocarcinoma 30.1 BAX MYC TP53
38 b cell prolymphocytic leukemia 30.1 CD5 MS4A1 MYC TP53
39 waldenstrom macroglobulinemia 30.1 BCL2 MS4A1 PAX5
40 glioblastoma 30.1 CCND1 CDKN1B MYC TP53
41 gastric cancer 29.9 BAX BCL2 CCND1 CDKN1B MYC TP53
42 leukemia, acute lymphoblastic 3 29.9 FOXP1 MME PAX5 TP53
43 leukemia, acute myeloid 29.9 CD5 MME MYC TP53
44 leukemia, chronic lymphocytic 28.6 AICDA BAX BCL10 BCL2 BCL6 CCND1
45 lymphoma, non-hodgkin, familial 27.3 AICDA BAX BCL10 BCL2 BCL6 CCND1
46 alk-positive large b-cell lymphoma 12.5
47 relapsed/refractory diffuse large b-cell lymphoma 12.5
48 primary cutaneous diffuse large b-cell lymphoma, leg type 12.4
49 epstein-barr virus-positive diffuse large b-cell lymphoma of the elderly 12.4
50 indolent b cell lymphoma 12.3

Graphical network of the top 20 diseases related to B-Cell Lymphomas:



Diseases related to B-Cell Lymphomas

Symptoms & Phenotypes for B-Cell Lymphomas

GenomeRNAi Phenotypes related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 BAX BCL10 BCL2 MALT1 TP53
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 BAX BCL10 BCL2 CCND1 MALT1 MYC

MGI Mouse Phenotypes related to B-Cell Lymphomas:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.33 CD5 CDKN1B IRF4 MALT1 MS4A1 MYC
2 immune system MP:0005387 10.32 AICDA BAX BCL10 BCL2 BCL6 CCND1
3 cellular MP:0005384 10.22 AICDA BAX BCL10 BCL2 BCL6 CCND1
4 endocrine/exocrine gland MP:0005379 10.16 TNFRSF8 TP53 BAX BCL10 BCL2 BCL6
5 integument MP:0010771 9.97 AICDA BCL2 CCND1 CD5 CDKN1B MME
6 mortality/aging MP:0010768 9.97 CDKN1B MALT1 MYC PAX5 REL TP53
7 hearing/vestibular/ear MP:0005377 9.91 BAX BCL2 CDKN1B MYC PAX5 TP53
8 liver/biliary system MP:0005370 9.8 TP53 BCL6 CCND3 CDKN1B MME MYC
9 neoplasm MP:0002006 9.65 AICDA BAX BCL2 CCND1 CCND3 CDKN1B
10 normal MP:0002873 9.28 AICDA BCL6 CCND1 CCND3 CD5 MYC

Drugs & Therapeutics for B-Cell Lymphomas

FDA approved drugs:

(show all 9)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Adcetris 17 45 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
2
Bexxar 17 45 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
3
Intron A 17 45 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
4
Mozobil 17 45 PLERIXAFOR Genzyme December 2008
5
Revlimid 17 45 LENALIDOMIDE Celgene June 2013
6
Rituxan 17 45 RITUXIMAB Biogen IDEC, Genentech November 1997
7
Treanda 17 45 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
8
Zevalin 17 45 IBRITUMOMAB TIUXETAN Biogen IDEC February 2002
9
Zydelig 17 45 IDELALISIB Gilead July 2014

Drugs for B-Cell Lymphomas (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 583)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
3
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 147-94-4 6253
4
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
5
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
6
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
7
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
8 Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-02-2 5743
10
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 23214-92-8 31703
11
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
12
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
13
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
14
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
15
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2 53643-48-4, 59917-39-4 40839
16
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1 15663-27-1 2767 441203 84093
17
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
18
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
19
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 657311 5754
20
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
21
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
22
Ledipasvir Approved Phase 4,Phase 2 1256388-51-8 67505836
23
Sofosbuvir Approved Phase 4,Phase 2 1190307-88-0 45375808
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
25
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 143 6006
26
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 31703
27 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
30 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
44 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1177-87-3
46 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1866)

# Name Status NCT ID Phase Drugs
1 Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old. Unknown status NCT00429065 Phase 4 Rituximab
2 Lymphoma in the Orbit Unknown status NCT01302912 Phase 4
3 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
4 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
5 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
6 Treatment of Diffuse Large B Cell Lymphoma Recruiting NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
7 Treatment of Relapsed /Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03376958 Phase 4 Apatinib
8 Reduced Chemotherapy in Low Risk DLBCL Recruiting NCT02752815 Phase 4 Rituximab;Cyclophosphamide;Epirubicin;Vincristine;Prednisone
9 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Recruiting NCT03229200 Phase 4 Ibrutinib
10 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
11 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Recruiting NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
12 To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Recruiting NCT02585947 Phase 4 Tenofovir
13 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma Active, not recruiting NCT01990534 Phase 4 Brentuximab vedotin
14 Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma Not yet recruiting NCT02992834 Phase 4
15 Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study Terminated NCT02717949 Phase 4 sofosbuvir/ledipasvir;sofosbuvir;Ribavirin
16 Trial of GemOx±R Regimen in First-line Treatment of Elderly Aggressive B Cell Lymphoma Unknown status NCT01670370 Phase 3 R-GemOx;GemOx
17 Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients Unknown status NCT00846157 Phase 3
18 Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. Unknown status NCT01805557 Phase 2, Phase 3 R-DHAP;BR-DHAP
19 Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma Unknown status NCT00499018 Phase 3 Rituximab;Ciclofosfamide;Doxorubicina;Vincristina;Prednisone;Pegfilgrastim;Mitoxantrone;ARA-C;Lenograstim;BCNU;ARA-C;VP-16;Ciclofosfamide;Doxorubicina;Vincristina
20 30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
21 TREatment of degeNerative and Neoplastic Diseases With Rituximab Unknown status NCT01277172 Phase 2, Phase 3
22 Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R Unknown status NCT00322218 Phase 3 Zevalin Therapeutic Regimen
23 Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
24 Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma Unknown status NCT00003650 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;vincristine sulfate
25 Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma Unknown status NCT00022685 Phase 3
26 Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Unknown status NCT00725231 Phase 3 chemotherapy
27 Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation Unknown status NCT00154440 Phase 3 proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
28 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
29 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
30 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
31 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
32 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
33 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
34 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
35 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
36 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
37 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
38 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
39 LMBA02 Protocol for Patients With a Burkitt Lymphoma Unknown status NCT00180882 Phase 3 rituximab
40 Treatment of Mature B-cell Lymphoma/Leukaemia Completed NCT00162656 Phase 3 half cyclophosphamide;without COPADM3;mini CYVE, without 3 maintenance courses;LMB B;LMB C
41 Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3 Everolimus;Everolimus Placebo
42 Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203) Completed NCT00147121 Phase 2, Phase 3 Rituximab + Standard CHOP;Rituximab + Bi-weekly CHOP
43 A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a Completed NCT01724021 Phase 3 Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP);Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP);Bendamustine;Rituximab;Rituximab;Rituximab;Rituximab
44 A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 Completed NCT00400478 Phase 3 Rituximab
45 A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib Completed NCT01324596 Phase 3 Intravenous;Bortezomib
46 A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma Completed NCT01649856 Phase 3 CHOP;rituximab [MabThera/Rituxan];rituximab [MabThera/Rituxan]
47 ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1 Completed NCT00140595 Phase 3 rituximab;doxorubicin;cyclophosphamide
48 R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma Completed NCT00144755 Phase 3 Darbepoetin alfa
49 ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma Completed NCT00169130 Phase 2, Phase 3 doxorubicin;cyclophosphamide
50 R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma Completed NCT00137995 Phase 3 Rituximab;Etoposide;Carboplatine;Ifosfamide + Mesna;Cisplatine;Cytosine Arabinoside;Dexamethasone;BCNU;Etoposide;Cytarabine;Melphalan

Search NIH Clinical Center for B-Cell Lymphomas

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about B-Cell Lymphomas cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, b-cell

Genetic Tests for B-Cell Lymphomas

Genetic tests related to B-Cell Lymphomas:

# Genetic test Affiliating Genes
1 B-Cell Lymphoma 28

Anatomical Context for B-Cell Lymphomas

MalaCards organs/tissues related to B-Cell Lymphomas:

38
B Cells, T Cells, Bone, Bone Marrow, Breast, Lymph Node, Liver

Publications for B-Cell Lymphomas

Articles related to B-Cell Lymphomas:

(show top 50) (show all 3996)
# Title Authors Year
1
Erratum: Epperla N, Maddocks KJ, Salhab M, et al. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Cancer. 2017;123:4411-4418. ( 29406586 )
2018
2
Complete response of diffuse large B-cell lymphoma after direct-acting antiviral therapy for hepatitis C virus. ( 29432921 )
2018
3
Bone Marrow Involvement of Epstein-Barr Virus-Positive Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma. ( 29214764 )
2018
4
Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER-Medicare Cohort. ( 29273217 )
2018
5
Some diffuse large B-cell lymphomas (DLBCLs) present with clone-dependent TTF-1 positivity. ( 29393528 )
2018
6
Primary breast diffuse large B-cell lymphoma: a population-based study from 1975 to 2014. ( 29423097 )
2018
7
Over-activated PD-1/PD-L1 axis facilitates the chemoresistance of diffuse large B-cell lymphoma cells to the CHOP regimen. ( 29435074 )
2018
8
Systemic diffuse large B-cell lymphoma masquerading as neovascular glaucoma. ( 29380792 )
2018
9
Two for One: B-Cell Lymphomas with Features of Marginal and Follicular Lymphomas. ( 29408811 )
2018
10
Burkitt lymphoma and diffuse large B-cell lymphoma: a unique case of a composite lymphoma of different clonal origin. ( 28583033 )
2018
11
Random skin biopsy for diagnosis of intravascular large B-cell lymphoma in a patient with hypoxemia and normal lung imaging. ( 29387769 )
2018
12
PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. ( 29112015 )
2018
13
Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B cell Lymphoma and Acute Myeloid Leukemia: A Report of Two Cases. ( 29321428 )
2018
14
Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance. ( 29168251 )
2018
15
Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma. ( 29427185 )
2018
16
Anti-ZIC4 associated paraneoplastic cerebellar degeneration in a patient with both diffuse large B-cell lymphoma and incidental smoldering multiple myeloma. ( 29249374 )
2018
17
Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy. ( 29271084 )
2018
18
Chemotherapy is administered to a minority of hospitalized patients with diffuse large B-cell lymphoma and is associated with less likelihood of death during hospitalization. ( 29438924 )
2018
19
Very low-dose versus standard dose radiation therapy for indolent primary cutaneous B-cell lymphomas: A retrospective study. ( 29332711 )
2018
20
Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.<i>Blood</i>. 2017;130(16):1800-1808. ( 29437609 )
2018
21
Primary Liver Diffuse Large B-Cell Lymphoma following Complete Response for Hepatitis C Infection after Direct Antiviral Therapy. ( 29393087 )
2018
22
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. ( 29416618 )
2018
23
Meningeal marginal zone B-cell lymphoma: The meningioma trap. ( 29331570 )
2018
24
T-Cell Large Granular Lymphocytic Leukemia and Coexisting B-Cell Lymphomas: A Study From the Bone Marrow Pathology Group. ( 29365010 )
2018
25
Targetable Metabolic Vulnerability in Diffuse Large B-Cell Lymphoma. ( 29397369 )
2018
26
Computer-driven quantitative image analysis in the assessment of tumor cell and T cell features in diffuse large B cell lymphomas. ( 29362889 )
2018
27
Novel insights into the disease dynamics of B-cell lymphomas in the Genomics Era. ( 29359812 )
2018
28
Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms. ( 29403080 )
2018
29
A Rare Manifestation of Primary Bone Lymphoma: Solitary Diffuse Large B-Cell Lymphoma of the Little Finger. ( 29398333 )
2018
30
Autopsy case report of intravascular large B-cell lymphoma with neoplastic PD-L1 expression. ( 29415979 )
2018
31
Intravascular Large B Cell Lymphoma of the Gallbladder. ( 29391332 )
2018
32
Hemophagocytic Lymphohistiocytosis Secondary to T Cell/Histiocyte-rich Large B Cell Lymphoma in an Adolescent Male. ( 29187030 )
2018
33
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. ( 29419431 )
2018
34
Concurrent mucosa-associated lymphoid tissue lymphoma with diffuse large B-cell lymphoma transformation and Hodgkin lymphoma of the neck. ( 29427189 )
2018
35
Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma. ( 29377256 )
2018
36
Primary mediastinal large B-cell lymphoma: Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20. ( 29049862 )
2018
37
High frequency and prognostic value of<i>MYD88</i>L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment. ( 29403563 )
2018
38
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. ( 29118007 )
2018
39
Interim FDG PET/CT in primary mediastinal diffuse large B-cell lymphoma: really almost useless procedure? ( 29397402 )
2018
40
Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group. ( 29193018 )
2018
41
Rare Variant of Intravascular Large B-Cell Lymphoma With Hemophagocytic Syndrome. ( 29356737 )
2018
42
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. ( 29413279 )
2018
43
Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma. ( 29428948 )
2018
44
De Novo CD5-Positive Primary Gastric Diffuse Large B-Cell Lymphoma Coexpressing MYC and BCL6: Towards a Proper Subset of Double-Hit, Triple-Hit and, Maybe, Quadruple-Hit B-Cell Lymphomas? ( 29399573 )
2018
45
B-cell lymphomas involving Waldeyer's ring characterized by distinctive clinical and histopathological features: a comparison of pediatric to adult patients. ( 28086220 )
2017
46
Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma. ( 28103885 )
2017
47
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. ( 27568520 )
2017
48
The clinicopathologic spectrum of mature aggressive B cell lymphomas. ( 28844114 )
2017
49
mTOR activity in AIDS-related diffuse large B-cell lymphoma. ( 28192480 )
2017
50
The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma. ( 28069569 )
2017

Variations for B-Cell Lymphomas

Cosmic variations for B-Cell Lymphomas:

9 (show all 25)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM44571 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 4
2 COSM10894 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 4
3 COSM35908 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2251G>A p.E751K 4
4 COSM35909 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.254G>A p.W85* 4
5 COSM35907 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2209C>A p.Q737K 4
6 COSM35911 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1354G>T p.E452* 4
7 COSM35970 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1421C>A p.T474N 4
8 COSM35913 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.905T>C p.L302P 4
9 COSM35969 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.503G>A p.W168* 4
10 COSM574 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.38G>T p.G13V 4
11 COSM566 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>T p.G12V 4
12 COSM581 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.181C>G p.Q61E 4
13 COSM586 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.183A>C p.Q61H 4
14 COSM562 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.34G>T p.G12C 4
15 COSM564 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>A p.G12D 4
16 COSM5416033 NFKBIE haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.782+5G>A p.? 4
17 COSM499 HRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.182A>G p.Q61R 4
18 COSM5036 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.202T>C p.Y68H 2
19 COSM5274 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.484G>C p.D162H 2
20 COSM37029 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.1937A>C p.Y646S 2
21 COSM37031 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.1936T>A p.Y646N 2
22 COSM12475 CDKN2A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.238C>T p.R80* 2
23 COSM21829 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.8138G>A p.R2713K 2
24 COSM22488 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.8494C>T p.R2832C 2
25 COSM21828 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.2932T>C p.S978P 2

Expression for B-Cell Lymphomas

Search GEO for disease gene expression data for B-Cell Lymphomas.

Pathways for B-Cell Lymphomas

Pathways related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 BCL10 BCL2 BCL6 CCND1 CDKN1B IRF4
2
Show member pathways
13.4 BCL2 BCL6 CCND1 IRF4 MYC TNFRSF8
3
Show member pathways
13.25 BAX BCL10 BCL2 CCND1 CDKN1B MALT1
4
Show member pathways
13.09 BAX BCL2 CCND1 CDKN1B MYC TP53
5
Show member pathways
13.01 BAX BCL2 CCND1 CCND3 CDKN1B MYC
6 12.87 BAX BCL2 CCND1 CCND3 CDKN1B MYC
7
Show member pathways
12.84 BAX BCL2 IRF4 MYC TP53
8
Show member pathways
12.8 BAX BCL2 CCND1 CDKN1B MYC TP53
9
Show member pathways
12.76 BCL10 CDKN1B MALT1 REL TP53
10
Show member pathways
12.63 BAX BCL2 MYC REL TP53
11
Show member pathways
12.62 BAX BCL2 CCND1 CDKN1B MYC TP53
12
Show member pathways
12.61 BAX BCL2 CCND1 CDKN1B TP53
13
Show member pathways
12.61 CCND1 CCND3 CDKN1B MYC TP53
14 12.54 BCL2 CCND1 CDKN1B FOXP1 MYC TP53
15
Show member pathways
12.53 BAX BCL2 CCND1 MYC REL
16 12.47 BAX CCND1 CCND3 MYC TP53
17
Show member pathways
12.46 BCL10 IRF4 MALT1 REL
18 12.44 AICDA BCL10 BCL6 IRF4 MALT1 PAX5
19
Show member pathways
12.42 BCL10 BCL6 IRF4 MALT1 MYC REL
20
Show member pathways
12.41 BAX CCND1 CCND3 CDKN1B MYC REL
21
Show member pathways
12.4 BCL2 CCND1 CCND3 MYC
22 12.4 CCND1 CCND3 CDKN1B MYC TP53
23
Show member pathways
12.4 BAX CCND1 CCND3 CDKN1B MYC TP53
24
Show member pathways
12.39 CCND1 CCND3 CDKN1B TP53
25 12.33 BCL2 CDKN1B MYC TP53
26 12.33 BAX CCND1 CCND3 CDKN1B REL TP53
27
Show member pathways
12.29 BAX BCL2 CCND1 TP53
28 12.29 BAX BCL10 BCL2 MALT1 MYC
29 12.27 BAX BCL10 BCL2 MALT1
30
Show member pathways
12.26 CCND1 CCND3 CDKN1B MYC
31 12.22 BAX CCND1 MYC TP53
32
Show member pathways
12.22 BAX BCL2 CCND1 CCND3 CDKN1B MYC
33 12.21 CCND1 CCND3 MYC TP53
34 12.2 BAX BCL2 CCND1 MYC TP53
35
Show member pathways
12.18 BAX CCND1 CDKN1B MYC TP53
36 12.11 BAX BCL2 BCL6 TP53
37 12.09 BAX BCL2 CCND1 CCND3 TP53
38 12.06 CCND1 CDKN1B MYC TP53
39 12.02 CCND1 CDKN1B MYC TP53
40 11.97 BCL2 BCL6 CCND1 IRF4 MYC TP53
41 11.97 BAX BCL6 CDKN1B MYC PAX5 REL
42 11.95 BAX BCL2 CCND1 CDKN1B
43 11.9 BCL10 BCL2 MALT1
44 11.88 CCND1 CCND3 CDKN1B MYC TP53
45 11.83 BAX MYC TP53
46 11.81 BCL2 CCND1 CDKN1B MYC PAX5
47 11.78 IRF4 MME MS4A1
48
Show member pathways
11.78 BCL2 REL TNFRSF8
49 11.77 CCND1 MYC TP53
50 11.77 CCND3 CDKN1B MYC

GO Terms for B-Cell Lymphomas

Cellular components related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.93 BCL2 BCL6 CCND1 CCND3 CDKN1B FOXP1
2 nucleus GO:0005634 9.58 AICDA BAX BCL10 BCL2 BCL6 CCND1
3 protein complex GO:0043234 9.5 BCL10 BCL2 CDKN1B MALT1 MYC PARP9
4 pore complex GO:0046930 9.37 BAX BCL2
5 CBM complex GO:0032449 9.26 BCL10 MALT1
6 cytosol GO:0005829 10.22 BAX BCL10 BCL2 CCND1 CCND3 CDKN1B
7 cytoplasm GO:0005737 10.2 AICDA BAX BCL10 BCL2 CCND1 CCND3

Biological processes related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.99 BAX BCL10 BCL6 TNFRSF8 TP53
2 response to drug GO:0042493 9.97 BCL2 CCND1 CDKN1B MYC TP53
3 positive regulation of transcription, DNA-templated GO:0045893 9.91 BCL10 FOXP1 IRF4 MYC PARP9 REL
4 negative regulation of cell proliferation GO:0008285 9.88 BAX BCL2 BCL6 CDKN1B TNFRSF8 TP53
5 regulation of cell cycle GO:0051726 9.86 BAX BCL2 CCND1 CCND3
6 negative regulation of transcription by RNA polymerase II GO:0000122 9.86 BCL6 CCND1 CCND3 MYC PARP9 PAX5
7 protein oligomerization GO:0051259 9.84 BAX BCL10 MALT1
8 apoptotic signaling pathway GO:0097190 9.83 BAX CD5 TNFRSF8
9 B cell differentiation GO:0030183 9.83 AICDA BCL2 BCL6
10 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.82 BAX CDKN1B TP53
11 response to cytokine GO:0034097 9.82 BCL2 REL TP53
12 humoral immune response GO:0006959 9.81 BCL2 MS4A1 PAX5
13 negative regulation of cell growth GO:0030308 9.8 BCL2 BCL6 CDKN1B TP53
14 regulation of apoptotic process GO:0042981 9.8 BAX BCL10 BCL2 BCL6 MALT1 TP53
15 cellular response to UV GO:0034644 9.77 BAX MYC TP53
16 ovarian follicle development GO:0001541 9.74 BAX BCL2 MYC
17 cellular response to organic substance GO:0071310 9.72 BAX BCL2 CCND1
18 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.7 BAX BCL2 TP53
19 cellular response to DNA damage stimulus GO:0006974 9.7 BAX BCL2 BCL6 CCND1 MYC PARP9
20 hypothalamus development GO:0021854 9.69 BAX MYC
21 negative regulation of fibroblast proliferation GO:0048147 9.69 BAX MYC TP53
22 regulation of mitochondrial membrane permeability GO:0046902 9.68 BCL2 TP53
23 response to molecule of bacterial origin GO:0002237 9.68 BCL10 MALT1
24 replicative senescence GO:0090399 9.68 MME TP53
25 response to UV-B GO:0010224 9.68 BCL2 TP53
26 positive regulation of histone deacetylation GO:0031065 9.67 BCL6 TP53
27 regulation of protein heterodimerization activity GO:0043497 9.67 BAX BCL2
28 mitotic G1 DNA damage checkpoint GO:0031571 9.67 CCND1 TP53
29 negative regulation of B cell apoptotic process GO:0002903 9.65 BCL6 FOXP1
30 regulation of protein homodimerization activity GO:0043496 9.63 BAX BCL2
31 B cell apoptotic process GO:0001783 9.63 BAX BCL10
32 response to fungus GO:0009620 9.62 BCL10 MALT1
33 re-entry into mitotic cell cycle GO:0000320 9.61 CCND1 MYC
34 regulation of T cell receptor signaling pathway GO:0050856 9.61 BCL10 MALT1
35 positive regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045737 9.61 CCND1 CCND3 CDKN1B
36 leukocyte homeostasis GO:0001776 9.58 BAX BCL2
37 regulation of nitrogen utilization GO:0006808 9.48 BAX BCL2
38 positive regulation of developmental pigmentation GO:0048087 9.46 BAX BCL2
39 positive regulation of cell cycle GO:0045787 9.26 CCND1 CDKN1B MYC TP53
40 response to gamma radiation GO:0010332 8.92 BAX BCL2 MYC TP53
41 cell proliferation GO:0008283 10.02 BAX BCL2 CD5 MYC TP53
42 negative regulation of apoptotic process GO:0043066 10.01 BCL2 BCL6 CDKN1B MALT1 MYC TP53

Molecular functions related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.93 BAX BCL2 FOXP1 MYC TP53
2 identical protein binding GO:0042802 9.92 AICDA BAX BCL10 BCL2 BCL6 FOXP1
3 protein kinase binding GO:0019901 9.89 BCL10 CCND1 CCND3 CDKN1B TP53
4 sequence-specific DNA binding GO:0043565 9.8 BCL2 BCL6 FOXP1 IRF4 MYC REL
5 chaperone binding GO:0051087 9.7 BAX CDKN1B TP53
6 protein phosphatase binding GO:0019903 9.69 BCL2 CDKN1B TP53
7 protease binding GO:0002020 9.67 BCL10 BCL2 MALT1 TP53
8 cyclin-dependent protein serine/threonine kinase activity GO:0004693 9.58 CCND1 CCND3 CDKN1B
9 kinase activator activity GO:0019209 9.48 BCL10 MALT1
10 BH3 domain binding GO:0051434 9.43 BAX BCL2
11 protein self-association GO:0043621 9.26 BCL10 FOXP1 MALT1 TP53
12 transcription factor binding GO:0008134 9.17 BCL10 BCL2 CCND1 FOXP1 IRF4 MYC
13 protein binding GO:0005515 10.13 AICDA BAX BCL10 BCL2 BCL6 CCND1
14 DNA binding transcription factor activity GO:0003700 10 BCL6 FOXP1 IRF4 MYC PAX5 REL

Sources for B-Cell Lymphomas

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....